Application of ionising radiation in healthcare - Revision history

Karen Clement at 18:04, 9 October 2019

2019-10-09T18:04:39Z

Karen Clement: Karen Clement moved page Application of ionising radiation in healthcare (demo) to Application of ionising radiation in healthcare

2019-10-09T18:03:56Z

Karen Clement moved page Application of ionising radiation in healthcare (demo) to Application of ionising radiation in healthcare

Karen Clement: /* Radiation Therapy */

2019-10-09T13:04:30Z

‎Radiation Therapy

Karen Clement: /* Biomedical Research */

2019-10-09T13:01:56Z

‎Biomedical Research

Karen Clement at 13:01, 9 October 2019

2019-10-09T13:01:22Z

Karen Clement: /* Biomedical Research */

2019-09-12T12:55:37Z

‎Biomedical Research

Karen Clement: /* Nuclear Medicine */

2019-09-12T12:53:46Z

‎Nuclear Medicine

Karen Clement: /* Radiation Therapy */

2019-09-12T12:49:24Z

‎Radiation Therapy

Karen Clement: /* Radiation Therapy */

2019-09-12T12:48:21Z

‎Radiation Therapy

Karen Clement: /* Interventional Procedures */

2019-09-12T12:41:51Z

‎Interventional Procedures

@@ Line 1: / Line 1: @@
 [[#top| ]]
-[[File:ICRPGuide.JPG|150px|thumb|right|link=Guide_to_Radiological_Protection_in_Healthcare_(demo)|Take me back to the ICRP's [[Guide_to_Radiological_Protection_in_Healthcare_(demo)|Guide to Radiological Protection in Healthcare]]!]]
+[[File:ICRPGuide.JPG|150px|thumb|right|link=Guide_to_Radiological_Protection_in_Healthcare|Take me back to the ICRP's [[Guide_to_Radiological_Protection_in_Healthcare|Guide to Radiological Protection in Healthcare]]!]]
 Application of ionising radiation in healthcare is basic and routine in contemporary medicine. Benefits to patients from such application have been established beyond doubt.<ref name="Pub105">[[ICRP Publication 105]] Radiological Protection in Medicine. Ann. ICRP 37(6), 2007.</ref> It is difficult to imagine a healthcare system without modern diagnostic imaging and image-guided interventional procedures. A survey of policy leaders in internal medicine rated computed tomography (CT) imaging as one of the main healthcare innovations in the 20th century<ref>Fuchs and Sox, 2001 [https://www.ncbi.nlm.nih.gov/pubmed/11558715]</ref>. The applications of ionising radiation in healthcare include the following topics.
@@ Line 154: / Line 154: @@
 '''[[#Top|Back to Top]]'''
-[[File:ICRPGuide.JPG|50px|link=Guide_to_Radiological_Protection_in_Healthcare_(demo)]]Take me back to the ICRP's [[Guide_to_Radiological_Protection_in_Healthcare_(demo)|Guide to Radiological Protection in Healthcare]]!
+[[File:ICRPGuide.JPG|50px|link=Guide_to_Radiological_Protection_in_Healthcare]]Take me back to the ICRP's [[Guide_to_Radiological_Protection_in_Healthcare|Guide to Radiological Protection in Healthcare]]!
 ==References==

← Older revision		Revision as of 13:04, 9 October 2019
Line 61:		Line 61:


−	Radiation therapy is used as a primary, curative treatment, as a palliative treatment, and/or as adjunctive therapy. It can be used pre-operatively or post-operatively, and in combination with chemotherapy, biologic agents, and hormonal agents. The radiation dose prescribed to achieve tumour control is often limited by the radiosensitivity of normal tissues, which are located around the tumour, and thus may result in early and late adverse side effects. Some adverse effects are unavoidable and often resolve spontaneously or with treatment. Serious adverse effects may occur and result from the proximity of sensitive normal tissues to the treatment area. However, such adverse side effects do not undermine the purpose of radiation therapy. Appropriate use of radiation therapy saves millions of lives every year. Even if only palliative treatment is possible, the therapy reduces suffering substantially. There are also a few non-malignant diseases whose treatment by radiation is a method of choice. ~~Note that palliative radiotherapy and radiotherapy of non-malignant diseases uses much lower doses, generally not inducing any acute side effects.~~	+	Radiation therapy is used as a primary, curative treatment, as a palliative treatment, and/or as adjunctive therapy. It can be used pre-operatively or post-operatively, and in combination with chemotherapy, biologic agents, and hormonal agents. The radiation dose prescribed to achieve tumour control is often limited by the radiosensitivity of normal tissues, which are located around the tumour, and thus may result in early and late adverse side effects. Some adverse effects are unavoidable and often resolve spontaneously or with treatment. Serious adverse effects may occur and result from the proximity of sensitive normal tissues to the treatment area. However, such adverse side effects do not undermine the purpose of radiation therapy. Appropriate use of radiation therapy saves millions of lives every year. Even if only palliative treatment is possible, the therapy reduces suffering substantially. There are also a few non-malignant diseases whose treatment by radiation is a method of choice.
−

	Radiation therapy has benefited greatly from technological advances over the past two decades, resulting in a wide variety of available delivery methods: Intensity-modulated radiation therapy (IMRT) utilizing techniques to quantify the critical normal tissue doses; Image-guided radiotherapy (IGRT) utilizing real-time imaging for treatment localization during radiotherapy; Stereotactic radiosurgery (SRS) delivering of a large dose per fraction to treat focal brain lesions and its extension, stereotactic body radiation therapy (SBRT), to treat focal lesions in the lung, spine, liver, pancreas, prostate and all parts of the body; Particle beam radiotherapy utilizing protons, neutrons or other heavy particles; Brachytherapy placing sealed radioactive sources near the tumor; Intraoperative radiotherapy (IORT) delivering to the surgical bed after removal of the tumor or to the tumor itself at the time of surgery; Unsealed sources delivering a radiopharmaceutical orally or parenterally; and Hyperthermia adding of heat to radiotherapy.		Radiation therapy has benefited greatly from technological advances over the past two decades, resulting in a wide variety of available delivery methods: Intensity-modulated radiation therapy (IMRT) utilizing techniques to quantify the critical normal tissue doses; Image-guided radiotherapy (IGRT) utilizing real-time imaging for treatment localization during radiotherapy; Stereotactic radiosurgery (SRS) delivering of a large dose per fraction to treat focal brain lesions and its extension, stereotactic body radiation therapy (SBRT), to treat focal lesions in the lung, spine, liver, pancreas, prostate and all parts of the body; Particle beam radiotherapy utilizing protons, neutrons or other heavy particles; Brachytherapy placing sealed radioactive sources near the tumor; Intraoperative radiotherapy (IORT) delivering to the surgical bed after removal of the tumor or to the tumor itself at the time of surgery; Unsealed sources delivering a radiopharmaceutical orally or parenterally; and Hyperthermia adding of heat to radiotherapy.

@@ Line 97: / Line 97: @@
 <br />
-[[file:mousescan.jpg|200px|thumb|'''FDG PET image of a mouse''' Source: Images Courtesy University of Manitoba Small Animal and Materials Imaging Core Facility]]
+[[file:mousescan.jpg|200px|thumb|'''FDG PET image of a mouse''' Images Courtesy University of Manitoba Small Animal and Materials Imaging Core Facility]]
 Ionising radiation is widely used in biomedical research. Such research is normally carried out in the laboratory and using different animal models. Research on normal tissue radiobiology aims at the investigation of the pathophysiological mechanisms and the consequences of ionising radiation. Pre-clinical in vivo studies in experimental animals largely focus on the characterisation of the pathophysiology of normal tissue reactions, the identification of potential biomarkers or the establishment of assays for predicting normal tissue toxicity of radiotherapy. Establishment of tumor xenograft models, involving implantation of human patient-derived tumors into immunodeficient animals, is a valuable research tool to investigate the biological effects of ionizing radiation on the disease mechanism of cancer.

@@ Line 8: / Line 8: @@
 <br/>
-[[file:figure 1.1.3.jpg|200px|left|thumb|'''Figure 1:''' Example of plain film radiography]]
+[[file:figure 1.1.3.jpg|200px|left|thumb|'''Example of plain film radiography''']]
-[[file:Brain-Computed tomography.jpg|200px|thumb|'''Figure 2:''' Example of brain Computed tomography ([https://www.researchgate.net/publication/5822266])]]
+[[file:Brain-Computed tomography.jpg|200px|thumb|'''Example of brain Computed tomography''' ([https://www.researchgate.net/publication/5822266])]]
-[[file:Pet_CT.jpg|200px|thumb|'''Figure 3:''' Example of true positive metastatic lesions detected by 18F-FDG PET/CT restaging (Courtesy: Eur. J. Nucl. Med. Mol. Imaging, 45: 1742/CC By 4.0)]]
+[[file:Pet_CT.jpg|200px|thumb|'''Example of true positive metastatic lesions detected by 18F-FDG PET/CT restaging''' Courtesy of Eur. J. Nucl. Med. Mol. Imaging, 45: 1742/CC By 4.0]]
 Diagnostic radiology, the imaging modalities using ionizing radiation, produces images of anatomical internal structures of human organs and physiological (functional) biological systems and helps significantly improve patient management and care in screening and diagnosis, assessing treatment response, predicting prognosis, and detecting disease recurrence. Modern diagnostic radiology assures faster, more precise diagnosis and enables monitoring of a large proportion of diseases. It has been estimated that in about one half of all cases, radiological procedures (conventional radiography, fluoroscopy, computed tomography) have a substantial impact on the speed of diagnosis and in a large fraction of cases they are of decisive importance in guiding patient management and therapy.
@@ Line 23: / Line 23: @@
 ==Interventional Procedures==
 <br/>
-[[file:PTA.jpg|200px|thumb|left|'''Figure 4:''' Percutaneous Transluminal Angioplasty (PTA) of the superficial femoral artery (SFA). Left image: subtotal calcified occlusion a) with many collaterals b); Right image: good patency after ballon PTA]]
+[[file:PTA.jpg|200px|thumb|left|'''Percutaneous Transluminal Angioplasty (PTA) of the superficial femoral artery (SFA). Left image: subtotal calcified occlusion a) with many collaterals b); Right image: good patency after ballon PTA''']]
 Interventional procedures using ionising radiation have revolutionised medicine in the past few decades for therapy and palliation, resulting in more patients being oﬀered treatments that would not have been possible before with  more invasive open surgery. The vast majority of interventional procedures are performed as “minimal invasive percutaneous therapies”.
@@ Line 57: / Line 57: @@
 <br/>
-[[file:Figure 1.4.1.jpg|200px|thumb|'''Figure 5:''' A TrueBEAM Radiotherapy System by Varian Medical Systems (Photo credit: Dr. W. Small, Loyola University Chicago)]]
+[[file:Figure 1.4.1.jpg|200px|thumb|'''A TrueBEAM Radiotherapy System by Varian Medical Systems''' Photo courtesy of Dr. W. Small, Loyola University Chicago]]
 Radiation therapy utilizes ionizing radiation to treat malignant and benign diseases. It has become a standard of care for treating many types of cancer. Current medical practice uses radiation therapy in about half of all newly diagnosed cancer cases. Radiation therapy works by exploiting radiobiological differences between cancer and normal cells/tissues, and by depositing radiation dose in cancer tumours while keeping doses to surrounding normal tissues below damaging thresholds as much as possible.
@@ Line 81: / Line 81: @@
 <br />
 {{#evt:service=youtube|id=https://youtu.be/0USC0C6qG9w|dimensions=500|container=frame|alignment=right|description=Video courtesy of the International Atomic Energy Agency}}
-[[file:Bone_Scan_2.jpg|left|200px|thumb|'''Figure 6:''' Example of an abnormal whole-body bone scan. Illustrates an abnormal bone scan in a patient which is marked with arrows. Source: Images Courtesy of Health Sciences Centre - Winnipeg, Manitoba.]]
+[[file:Bone_Scan_2.jpg|left|200px|thumb|'''Example of an abnormal whole-body bone scan. Illustrates an abnormal bone scan in a patient which is marked with arrows.''' Images Courtesy of Health Sciences Centre - Winnipeg, Manitoba.]]
 Nuclear medicine uses radioactive substances, called radiopharmaceuticals, in the diagnosis and treatment of a range of diseases. These substances are chosen or especially developed to be taken up predominantly by one organ or one type of cell in the body. Nuclear medicine offers unique diagnostic information in oncology, cardiology, endocrinology, neurology, nephrology, urology and other areas. Such information is not obtainable, or obtainable only with less accuracy, by other modalities. For nuclear medicine diagnostic procedures, trace amounts of radiopharmaceuticals are administered to patients through injection into veins (intravenous), skin (intradermal) or tissues (intraparenchymal) as well as breathing in (inhalation) or eating/drinking (ingestion). After intake, the function, or physiology, of various tissues, organs or organ systems can be demonstrated. For example, in cancer patients, nuclear medicine imaging can be used for diagnosis (i.e. is a cancer present), staging (i.e. how far has it spread), assessment of response to therapy or of possible disease recurrence. Nuclear medicine cameras are now commonly combined with a CT unit (e.g. hybrid SPECT/CT and PET/CT) which allows precise anatomic localisation of pathology.
-[[file:SPECT_CT_gamma.jpg|200px|thumb|'''Figure 7:''' Example of a SPECT/CT gamma camera (Source: © 2018 Siemens Healthcare GmbH. All Rights Reserved. Product photo provided courtesy of Siemens Healthcare GmbH) ]]
+[[file:SPECT_CT_gamma.jpg|200px|thumb|'''Example of a SPECT/CT gamma camera Source: © 2018 Siemens Healthcare GmbH.''' All Rights Reserved. Product photo provided courtesy of Siemens Healthcare GmbH ]]
 Nuclear medicine procedures for treatment are non-invasive and present no risk of direct complications to patients, but limited to several well-established situations where killing hyperfunctioning or malignant cells is important (for example hyperthyroidism, cancer of the thyroid, degenerative and inflammatory diseases of joints, palliative treatment of metastases to the skeleton). In addition, there are many studies showing significant potential for radio-labelled antibodies and receptor-avid peptides to be used in the treatment of several malignancies.
@@ Line 97: / Line 97: @@
 <br />
+[[file:mousescan.jpg|200px|thumb|'''FDG PET image of a mouse''' Source: Images Courtesy University of Manitoba Small Animal and Materials Imaging Core Facility]]
 Ionising radiation is widely used in biomedical research. Such research is normally carried out in the laboratory and using different animal models. Research on normal tissue radiobiology aims at the investigation of the pathophysiological mechanisms and the consequences of ionising radiation. Pre-clinical in vivo studies in experimental animals largely focus on the characterisation of the pathophysiology of normal tissue reactions, the identification of potential biomarkers or the establishment of assays for predicting normal tissue toxicity of radiotherapy. Establishment of tumor xenograft models, involving implantation of human patient-derived tumors into immunodeficient animals, is a valuable research tool to investigate the biological effects of ionizing radiation on the disease mechanism of cancer.
@@ Line 110: / Line 110: @@
 {{#evt:service=youtube|id=https://youtu.be/V6VZspB0pAQ|dimensions=500|container=frame|alignment=right|description=Video courtesy of the International Atomic Energy Agency}}
-[[file:LINAC_dog.jpg|200px|left|thumb|'''Figure 8:''' Linear accelerator treatment of a dog with a brain tumour (Photo courtesy of J. Benoit)]]
+[[file:LINAC_dog.jpg|200px|left|thumb|'''Linear accelerator treatment of a dog with a brain tumour''' Photo courtesy of J. Benoit]]
 Just as in human medicine, the use of  ionising radiation in veterinary care serves to provide or assist in providing a diagnosis, to guide an interventional procedure or to provide a direct radiation-induced therapeutic benefit.  The use of diagnostic radiology is widespread in veterinary care, in veterinary clinics or in private practices. Smaller companion animals are typically radiographed at the practice or clinic, whereas larger animals may also be radiographed at farms, zoos, or at riding and selling stables. Film-screen radiography is being replaced more and more by digital imaging techniques; CT and CBCT scanning have become routinely available in larger animal clinics. Fluoroscopically guided interventional procedures are also used in veterinary medicine. In these procedures, the radiation serves to provide dynamic, real-time images. The images will guide the anatomically correct delivery of treatments and will often allow real-time visualization of the results of the intervention.
@@ Line 117: / Line 117: @@
-[[file:Portable_PET_1.6.jpg|200px|thumb|'''Figure 9:''' A portable PET scanner being used for diagnosis of the left hind-leg of a horse (Photo courtesy of Dr. Spriet, UC Davis Veterinary Medicine, USA)]]
+[[file:Portable_PET_1.6.jpg|200px|thumb|'''A portable PET scanner being used for diagnosis of the left hind-leg of a horse''' Photo courtesy of Dr. Spriet, UC Davis Veterinary Medicine, USA]]
 In therapeutic nuclear medicine procedures a much higher dose (“activity”) of radioactive substances is administered to the animal. The radiation dose delivered to the targeted tissue or organ then becomes so high that cells within this tissue or organ are inhibited in their proliferation or even eliminated. If a cancer is being targeted, complete elimination of the cancerous growth is the desired objective. But in treating other diseases such as hyper functioning of the thyroid gland or inflammation of the joints, inhibition or partial destruction may be sufficient for achieving the desired clinical goal. In the more classical radiotherapy, radiation generated outside the animal patient is also used to eliminate tissues that are undesired. Most often this will be used for treating animal patients affected by cancer.

@@ Line 101: / Line 101: @@
-Studies involving radiation exposure of patients adds another level of risk that must be evaluated by an institutional ethics review board with assistance of a radiation expert or radiation safety committee. In all investigations involving exposure of humans, a careful estimation of the radiation dose to the patients or volunteers should be made. The associated risks should then be weighted against the benefits for the patients or the society when volunteers are involved. A reasonable alternative is the ex-vivo exposure of tumor specimen, human blood or skin samples obtained from patients or healthy volunteers, to avoid the hazard of radiation exposure. Approval by an institutional ethics review board or human studies committee must be obtained prior to conducting human subject research. The researchers' role is to conduct their research ethically while maximizing benefits to the society and minimizing harm to the participants. ICRP has provided recommendations in the guidance [[ICRP Publication 105]] Radiological Protection in Medicine and a previous [[ICRP Publication 62]] Radiological Protection in Biomedical Research.
+Studies involving radiation exposure of patients adds another level of risk that must be evaluated by an institutional ethics review board with assistance of a radiation expert or radiation safety committee. In all investigations involving exposure of humans, a careful estimation of the radiation dose to the patients or volunteers should be made. The associated risks should then be weighted against the benefits for the patients or the society when volunteers are involved. A reasonable alternative is the ex-vivo exposure of tumor specimen, human blood or skin samples obtained from patients or healthy volunteers, to avoid the hazard of radiation exposure. Approval by an institutional ethics review board or human studies committee must be obtained prior to conducting human subject research. The researchers' role is to conduct their research ethically while maximizing benefits to the society and minimizing harm to the participants. ICRP has provided recommendations in the guidance [[ICRP Publication 105]] Radiological Protection in Medicine<ref name="Pub105"/> and a previous [[ICRP Publication 62]] Radiological Protection in Biomedical Research<ref name="Pub062">[[ICRP Publication 62]] Radiological Protection in Biomedical Research. Ann. ICRP 22(3), 1991.</ref>.
 '''[[#Top|Back to Top]]'''
 ==Veterinary Medicine==

← Older revision	Revision as of 18:03, 9 October 2019
(No difference)

← Older revision		Revision as of 12:53, 12 September 2019
Line 90:		Line 90:


−	A patient undergoing nuclear medicine imaging or treatment becomes a radiation source and remains “radioactive” after the radiopharmaceutical has been administered. Radiation protection advice depends on the specific radioisotope and its radiopharmaceutical form administered and whether the procedure is diagnostic or therapeutic. However, the general principles of the ICRP system of radiological protection apply in nuclear medicine as they do for other medical imaging modalities using ionising radiation. In addition [[ICRP Publication 52]] Protection of the Patient in Nuclear Medicine (and Statement from the 1987 Como Meeting of ICRP) and [[ICRP Publication 94]] Release of Patients after Therapy with Unsealed Radionuclides provide recommendations and guidance on the protection and release of patients after therapy with unsealed radionuclides (e.g. post 131 Iodine therapy for thyroid cancer), and [[ICRP Publication 128]] Radiation Dose to Patients from Radiopharmaceuticals: A Compendium of Current Information Related to Frequently Used Substances provides dose coefficients to patients from radiopharmaceuticals.	+	A patient undergoing nuclear medicine imaging or treatment becomes a radiation source and remains “radioactive” after the radiopharmaceutical has been administered. Radiation protection advice depends on the specific radioisotope and its radiopharmaceutical form administered and whether the procedure is diagnostic or therapeutic. However, the general principles of the ICRP system of radiological protection apply in nuclear medicine as they do for other medical imaging modalities using ionising radiation. In addition [[ICRP Publication 52]] Protection of the Patient in Nuclear Medicine (and Statement from the 1987 Como Meeting of ICRP)<ref name="Pub052">[[ICRP Publication 52]]Protection of the Patient in Nuclear Medicine. Ann. ICRP 17(4), 1987.</ref> and [[ICRP Publication 94]] Release of Patients after Therapy with Unsealed Radionuclides<ref name="Pub094">[[ICRP Publication 94]] Release of patients after therapy with unsealed radionuclides. Ann. ICRP 34(2), 2004.</ref> provide recommendations and guidance on the protection and release of patients after therapy with unsealed radionuclides (e.g. post 131 Iodine therapy for thyroid cancer), and [[ICRP Publication 128]] Radiation Dose to Patients from Radiopharmaceuticals: A Compendium of Current Information Related to Frequently Used Substances<ref name="Pub128">[[ICRP Publication 128]] Radiation Dose to Patients from Radiopharmaceuticals A Compendium of Current Information Related to Frequently Used Substances. Ann. ICRP 44(2S), 2015.</ref> provides dose coefficients to patients from radiopharmaceuticals.

	'''[[#Top\|Back to Top]]'''		'''[[#Top\|Back to Top]]'''

@@ Line 70: / Line 70: @@
 <ul>
-<li>[[ICRP Publication 112]] Preventing Accidental Exposures from New External Beam Radiation Therapy Technologies<ref name="Pub112">[[Publication 112]] Preventing Accidental Exposures from New External Beam Radiation Therapy Technologies. Ann. ICRP 39(4), 2009.</ref> provides recommendation and guidance on preventing accidental exposures from new external beam radiation therapy technologies</li>
+<li>[[ICRP Publication 112]] Preventing Accidental Exposures from New External Beam Radiation Therapy Technologies<ref name="Pub112">[[ICRP Publication 112]] Preventing Accidental Exposures from New External Beam Radiation Therapy Technologies. Ann. ICRP 39(4), 2009.</ref> provides recommendation and guidance on preventing accidental exposures from new external beam radiation therapy technologies</li>
-<li>[[ICRP Publication 97]] Prevention of High-dose-rate Brachytherapy Accidents<ref name="Pub097">[[Publication 97]] Prevention of High-dose-rate Brachytherapy Accidents. Ann. ICRP 35(2), 2005.</ref> and [[ICRP Publication 98]] Radiation Safety Aspects of Brachytherapy for Prostate Cancer using Permanently Implanted Sources<ref name="Pub098">[[Publication 98]] Radiation Safety Aspects of Brachytherapy for Prostate Cancer using Permanently Implanted Sources. Ann. ICRP 35(3), 2005.</ref> discuss safety aspects of brachytherapy</li>
+<li>[[ICRP Publication 97]] Prevention of High-dose-rate Brachytherapy Accidents<ref name="Pub097">[[ICRP Publication 97]] Prevention of High-dose-rate Brachytherapy Accidents. Ann. ICRP 35(2), 2005.</ref> and [[ICRP Publication 98]] Radiation Safety Aspects of Brachytherapy for Prostate Cancer using Permanently Implanted Sources<ref name="Pub098">[[ICRP Publication 98]] Radiation Safety Aspects of Brachytherapy for Prostate Cancer using Permanently Implanted Sources. Ann. ICRP 35(3), 2005.</ref> discuss safety aspects of brachytherapy</li>
-<li>[[ICRP Publication 127]] Radiological Protection in Ion Beam Radiotherapy addresses protection in ion beam radiotherapy<ref name="Pub127">[[Publication 127]] Radiological Protection in Ion Beam Radiotherapy. Ann. ICRP 43(4), 2014.</ref></li>
+<li>[[ICRP Publication 127]] Radiological Protection in Ion Beam Radiotherapy addresses protection in ion beam radiotherapy<ref name="Pub127">[[ICRP Publication 127]] Radiological Protection in Ion Beam Radiotherapy. Ann. ICRP 43(4), 2014.</ref></li>
-<li>[[ICRP Publication 86]] Prevention of Accidents to Patients Undergoing Radiation Therapy covers prevention of accidental exposures to patients undergoing radiation therapy<ref name="Pub086">[[Publication 86]] Prevention of Accidental Exposures to Patients Undergoing Radiation Therapy. Ann. ICRP 30(3), 2000.</ref></li>
+<li>[[ICRP Publication 86]] Prevention of Accidents to Patients Undergoing Radiation Therapy covers prevention of accidental exposures to patients undergoing radiation therapy<ref name="Pub086">[[ICRP Publication 86]] Prevention of Accidental Exposures to Patients Undergoing Radiation Therapy. Ann. ICRP 30(3), 2000.</ref></li>
 </ul>

@@ Line 34: / Line 34: @@
 <ul>
-<li>[[ICRP Publication 139]] Occupational Radiological Protection in Interventional Procedures<ref name="Pub 139">[[ICRP Publication 139]] Occupational Radiological Prodection in Interventional Procedures, Ann, ICRP 47(2), 2018.</ref></li>
+<li>[[ICRP Publication 139]] Occupational Radiological Protection in Interventional Procedures<ref name="Pub139">[[ICRP Publication 139]] Occupational Radiological Prodection in Interventional Procedures, Ann, ICRP 47(2), 2018.</ref></li>
-<li>[[ICRP Publication 121]] Radiological Protection in Paediatric Diagnostic and Interventional Radiology<ref name="Pub 121"/></li>
+<li>[[ICRP Publication 121]] Radiological Protection in Paediatric Diagnostic and Interventional Radiology<ref name="Pub121"/></li>
-<li>[[ICRP Publication 120]] Radiological Protection in Cardiology<ref name="Pub 120">[[ICRP Publication 120]] Radiological Protection in Cardiology. Ann. ICRP 42(1), 2013.</ref></li>
+<li>[[ICRP Publication 120]] Radiological Protection in Cardiology<ref name="Pub120">[[ICRP Publication 120]] Radiological Protection in Cardiology. Ann. ICRP 42(1), 2013.</ref></li>
-<li>[[ICRP Publication 117]] Radiological Protection in Fluoroscopically Guided Procedures outside the Imaging Department<ref name="Pub 117">[[ICRP Publication 117]] Radiological Protection in Fluoroscopically Guided Procedures Performed Outside the Imaging Department. Ann. ICRP 40(6), 2010.</ref></li>
+<li>[[ICRP Publication 117]] Radiological Protection in Fluoroscopically Guided Procedures outside the Imaging Department<ref name="Pub117">[[ICRP Publication 117]] Radiological Protection in Fluoroscopically Guided Procedures Performed Outside the Imaging Department. Ann. ICRP 40(6), 2010.</ref></li>
 <li>[[ICRP Publication 105]] Radiological Protection in Medicine<ref name="Pub105"/></li>
-<li>[[ICRP Publication 85]] Avoidance of Radiation Injuries from Medical Interventional Procedures<ref name="Pub 085">[[ICRP Publication 85]] Avoidance of Radiation Injuries from Medical Interventional Procedures. Ann. ICRP 30(2), 2000.</ref></li>
+<li>[[ICRP Publication 85]] Avoidance of Radiation Injuries from Medical Interventional Procedures<ref name="Pub085">[[ICRP Publication 85]] Avoidance of Radiation Injuries from Medical Interventional Procedures. Ann. ICRP 30(2), 2000.</ref></li>
 </ul>